يحاول ذهب - حر
Ensuring Biotech Startup Success Stories
BioSpectrum India May 2025
|Bio Spectrum
According to the Indian BioEconomy Report 2025, the number of biotech startups has more than doubled from 4237 in 2020 to 10,075 in 2024.
-
However, there has been a 13.1 per cent decline in 2024 with new startup registrations, as compared to the previous years. While the number of new startups kept increasing between 2020 and 2023, ranging between 26 and 30 per cent, 2024 saw only a 16-18 per cent rise in the number. Does this new trend suggest a potential stabilisation of the existing startups or a funding crunch for the new entrants? Or the growth of biotech startups in the country is simply following a numbers game. Let's find out.
In 2024, the bioeconomy of India reached a value of $165.7 billion, reflecting strong growth across biopharma, bioindustrial production, research services, and agricultural biotechnology. The India Bioeconomy Report 2025, prepared by the Association of Biotechnology Led Enterprises (ABLE), states that in 2023, the bioeconomy registered a 10 per cent growth, while in 2024, it registered a 9.7 per cent growth.
The report also reveals that the biotech startup sector has shown a decrease in growth rate in 2024 compared to previous years between 2020 and 2023. A similar dip was witnessed back in 2019 after considerable jumps from 2016 to 2018.
On the other hand, in 2022, biotech startups saw 31 deals totalling $938.8 million, while 2023 saw a dip with only 16 deals worth $199.6 million. The year 2024 further witnessed recovery and is estimated to close at $700 million with over two dozen deals.
These fluctuations might be governed by factors such as market saturation, increased competition, emerging new technologies, or limited funding.
As a recent development to harness the biotech potential in different parts of the country, the government has announced the development of regional Biotechnology Industry Research Assistance Council (BIRAC) centres across India, as a collaboration between the Centre and States.
هذه القصة من طبعة BioSpectrum India May 2025 من Bio Spectrum.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من Bio Spectrum
Bio Spectrum
Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility
Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).
1 min
December 2025
Bio Spectrum
Motorica strengthens India presence with appointment of Kavinder Beniwal as COO
Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.
1 min
December 2025
Bio Spectrum
Cabinet approves major expansion of PG and UG medical education capacity
Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.
1 min
December 2025
Bio Spectrum
Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President
The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.
1 min
December 2025
Bio Spectrum
PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO
Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).
1 min
December 2025
Bio Spectrum
Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership
The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.
1 min
December 2025
Bio Spectrum
"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"
Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;
4 mins
December 2025
Bio Spectrum
"AI is a transformative enabler that's reshaping how science is conducted in labs"
2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:
4 mins
December 2025
Bio Spectrum
Supporting India's Biopharma Expansion with Advanced, High-Performance Media
Kent Wang graduated from East China University of Science and Technology in Biochemical Engineering. He has over 12 years of experience in upstream biopharmaceutical process development, contributing to clinical projects including monoclonal antibodies, bispecific antibodies, and ADCs. He is well-versed in CHO cell metabolism and culture media characteristics, and has optimized critical quality attributes such as glycosylation, charge variants, fragmentation, aggregation, and amino acid oxidation. Previously at Shanghai Pharmaceuticals Group and 3S Bio, he now serves as Senior R&D Director at Duoning Biotech, focusing on serum-free cell culture media development. He established a comprehensive platform for media formulation and product development, leading his team to create a diverse portfolio of media for CHO, HEK293, insect, vaccine, hybridoma, and lymphocyte cell lines, leveraging cell metabolism insights and big data modeling.
4 mins
December 2025
Bio Spectrum
Corning and SGD Pharma inaugurate glass tubing facility in Telangana for pharma packaging
Corning Inc and SGD Pharma have announced the inauguration of a new glass tubing facility in Telangana, which will expand pharmaceutical manufacturing in the region.
1 min
December 2025
Listen
Translate
Change font size
